Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02808832
Other study ID # U54CA153708
Secondary ID
Status Completed
Phase N/A
First received June 16, 2016
Last updated September 12, 2016
Start date September 2010
Est. completion date August 2016

Study information

Verified date September 2016
Source Meharry Medical College
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to develop, deliver and evaluate a provider intervention for mothers and their children to encourage receipt of the human papillomavirus (HPV) vaccine in the children and appropriate cervical cancer screening in the mothers.


Description:

In this study the investigators utilized Community Based Participatory Research approaches in combination with our previous and ongoing research, patient and provider education materials available from professional organizations, and qualitative information obtained from provider in-depth interviews and parent/daughter focus groups to develop a provider intervention to encourage receipt of the HPV vaccine, and appropriate cancer screening in African Americans and Hispanics. A focus of the study was the formation of a Community Advisory Board (CAB) which provided input into the development and modification of the provider intervention. Safety net clinics in Nashville and Memphis served as intervention sites, and in Chattanooga and Nashville (Meharry) served as control sites. Mothers and children at the intervention sites viewed a 5-minute video in the exam room during any visit type before seeing the provider, and received an information sheet with a list of suggested questions to ask the provider. Mothers and children at the control sites received usual care. The selected study sites identified cervical cancer screening as a priority area based on the needs assessments conducted as part of the Meharry Medical College Community Health Center-Community Network Program (CHC-CNP). The investigators conducted pre- and post-intervention quantitative surveys with mothers and their children to evaluate whether the provider intervention was effective in improving HPV vaccination coverage, and cervical cancer screening rates. The investigators abstracted medical records and have indicated this in the HIPAA privacy form. After conducting pre- and post-intervention surveys and abstracting medical records, the investigators found that increasing HPV vaccine uptake requires more intensive, multicomponent interventions.


Recruitment information / eligibility

Status Completed
Enrollment 806
Est. completion date August 2016
Est. primary completion date March 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 9 Years and older
Eligibility Inclusion Criteria:

- Being seen as a pediatric patient at a study clinic on the day of enrollment

- Self-identified African American or Hispanic

- Aged 9-18 years (mother accompanying child to clinic visit had no age limit)

- Had received no doses of HPV vaccine or received one shot and was overdue for the second dose (three or more months after the first dose was given) prior to the clinic visit

Exclusion Criteria:

- Already having received two or more doses of HPV vaccine

- Mother or female guardian (referred to as "mother" henceforth) not accompanying the child

- Plans to move away from the clinic catchment area within the next 12 months

- Not completing the baseline assessment prior to entering the exam room

- Mother not providing or unable to give consent

- Child not giving assent.

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Behavioral:
Educational materials
5-minute video and information sheet with a list of suggested questions to ask the provider

Locations

Country Name City State
United States Meharry Medical College Nashville Tennessee

Sponsors (5)

Lead Sponsor Collaborator
Meharry Medical College Matthew Walker Comprehensive Health Center, Memphis Health Center, Southside/Dodson Avenue Community Health Centers, Vanderbilt University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of children participants who completed the 3-dose HPV vaccine series Although completion of the 3-dose HPV vaccine series is recommended within 6 months, the investigators measured completion within 12 months. 12 months No
Secondary Number of mother participants who received appropriate cervical cancer screening Cervical cancer screening is no longer recommended annually so the investigators measured receipt of a Pap smear as needed within a 12 month period. 12 months No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03225443 - Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy N/A
Recruiting NCT01373723 - Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer N/A
Terminated NCT01194609 - A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer Phase 1/Phase 2
Terminated NCT01234480 - Intended Use Study of the BD SurePath Plus™ Pap
Completed NCT01014026 - Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention Phase 3
Terminated NCT01075412 - FLT PET Imaging for Cervical Cancer Phase 2
Completed NCT02865889 - Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications N/A
Completed NCT00377845 - Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear. Phase 0
Recruiting NCT05531981 - Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
Recruiting NCT05393440 - First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer Phase 1
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT02866006 - Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer Phase 1/Phase 2
Completed NCT02320578 - 2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial N/A
Completed NCT03270995 - Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Not yet recruiting NCT05065853 - Urinary and Vaginal HPV Testing in Cervical Cancer Screening
Completed NCT01231945 - Low-Cost Molecular Cervical Cancer Screening Study N/A
Completed NCT01717391 - [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Phase 2
Active, not recruiting NCT04947605 - Epidemiological Landscape of Cervical Cancer in Latin America
Recruiting NCT06124040 - Sexual Function, Coping and Dyadic Coping in Patients With Cervical Cancer